JP2018526028A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018526028A5 JP2018526028A5 JP2018530657A JP2018530657A JP2018526028A5 JP 2018526028 A5 JP2018526028 A5 JP 2018526028A5 JP 2018530657 A JP2018530657 A JP 2018530657A JP 2018530657 A JP2018530657 A JP 2018530657A JP 2018526028 A5 JP2018526028 A5 JP 2018526028A5
- Authority
- JP
- Japan
- Prior art keywords
- item
- seq
- car
- isolated
- vector
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 56
- 210000004027 cell Anatomy 0.000 claims description 43
- 239000013598 vector Substances 0.000 claims description 39
- 239000012642 immune effector Substances 0.000 claims description 30
- 229940121354 immunomodulator Drugs 0.000 claims description 30
- 206010028980 Neoplasm Diseases 0.000 claims description 29
- 239000012634 fragment Substances 0.000 claims description 18
- 229920001184 polypeptide Polymers 0.000 claims description 17
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 17
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 17
- CZOGCRVBCLRHQJ-WHWAGLCYSA-N N-acetyl-alpha-neuraminyl-(2->6)-N-acetyl-alpha-D-galactosamine Chemical compound O[C@@H]1[C@H](O)[C@@H](NC(=O)C)[C@@H](O)O[C@@H]1CO[C@@]1(C(O)=O)O[C@@H]([C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C1 CZOGCRVBCLRHQJ-WHWAGLCYSA-N 0.000 claims description 14
- 239000000427 antigen Substances 0.000 claims description 14
- 102000036639 antigens Human genes 0.000 claims description 14
- 108091007433 antigens Proteins 0.000 claims description 14
- 230000011664 signaling Effects 0.000 claims description 13
- 102000003886 Glycoproteins Human genes 0.000 claims description 12
- 108090000288 Glycoproteins Proteins 0.000 claims description 12
- 230000000139 costimulatory effect Effects 0.000 claims description 12
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 10
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 9
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 9
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims description 9
- 102100027207 CD27 antigen Human genes 0.000 claims description 8
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims description 8
- 102000040430 polynucleotide Human genes 0.000 claims description 7
- 108091033319 polynucleotide Proteins 0.000 claims description 7
- 239000002157 polynucleotide Substances 0.000 claims description 7
- -1 CDδ Proteins 0.000 claims description 6
- 102000015728 Mucins Human genes 0.000 claims description 6
- 108010063954 Mucins Proteins 0.000 claims description 6
- 230000001177 retroviral effect Effects 0.000 claims description 5
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims description 4
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims description 4
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims description 4
- 101000946860 Homo sapiens T-cell surface glycoprotein CD3 epsilon chain Proteins 0.000 claims description 4
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims description 4
- 102100035794 T-cell surface glycoprotein CD3 epsilon chain Human genes 0.000 claims description 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 4
- 102000007269 CA-125 Antigen Human genes 0.000 claims description 3
- 108010008629 CA-125 Antigen Proteins 0.000 claims description 3
- 102000007298 Mucin-1 Human genes 0.000 claims description 3
- 108010008707 Mucin-1 Proteins 0.000 claims description 3
- 101710155891 Mucin-like protein Proteins 0.000 claims description 3
- 101000844719 Mus musculus Deleted in malignant brain tumors 1 protein Proteins 0.000 claims description 3
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 3
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims description 3
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 3
- 125000006850 spacer group Chemical group 0.000 claims description 3
- 101150013553 CD40 gene Proteins 0.000 claims description 2
- 210000001239 CD8-positive, alpha-beta cytotoxic T lymphocyte Anatomy 0.000 claims description 2
- 102100035793 CD83 antigen Human genes 0.000 claims description 2
- 102100037904 CD9 antigen Human genes 0.000 claims description 2
- 102100025466 Carcinoembryonic antigen-related cell adhesion molecule 3 Human genes 0.000 claims description 2
- 102100024965 Caspase recruitment domain-containing protein 11 Human genes 0.000 claims description 2
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims description 2
- 102100029360 Hematopoietic cell signal transducer Human genes 0.000 claims description 2
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 claims description 2
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 claims description 2
- 101000738354 Homo sapiens CD9 antigen Proteins 0.000 claims description 2
- 101000914337 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 3 Proteins 0.000 claims description 2
- 101000761179 Homo sapiens Caspase recruitment domain-containing protein 11 Proteins 0.000 claims description 2
- 101000990188 Homo sapiens Hematopoietic cell signal transducer Proteins 0.000 claims description 2
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 claims description 2
- 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 claims description 2
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 claims description 2
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims description 2
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims description 2
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims description 2
- 101000914496 Homo sapiens T-cell antigen CD7 Proteins 0.000 claims description 2
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 claims description 2
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims description 2
- 101000763579 Homo sapiens Toll-like receptor 1 Proteins 0.000 claims description 2
- 101000763537 Homo sapiens Toll-like receptor 10 Proteins 0.000 claims description 2
- 101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 claims description 2
- 101000831496 Homo sapiens Toll-like receptor 3 Proteins 0.000 claims description 2
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 claims description 2
- 101000669460 Homo sapiens Toll-like receptor 5 Proteins 0.000 claims description 2
- 101000669406 Homo sapiens Toll-like receptor 6 Proteins 0.000 claims description 2
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 claims description 2
- 101000800483 Homo sapiens Toll-like receptor 8 Proteins 0.000 claims description 2
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims description 2
- 101000818543 Homo sapiens Tyrosine-protein kinase ZAP-70 Proteins 0.000 claims description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims description 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims description 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims description 2
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 claims description 2
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 claims description 2
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims description 2
- 102100034709 Lymphocyte cytosolic protein 2 Human genes 0.000 claims description 2
- 101710195102 Lymphocyte cytosolic protein 2 Proteins 0.000 claims description 2
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims description 2
- 102100027208 T-cell antigen CD7 Human genes 0.000 claims description 2
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 claims description 2
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims description 2
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 claims description 2
- 102100027010 Toll-like receptor 1 Human genes 0.000 claims description 2
- 102100027009 Toll-like receptor 10 Human genes 0.000 claims description 2
- 102100024333 Toll-like receptor 2 Human genes 0.000 claims description 2
- 102100024324 Toll-like receptor 3 Human genes 0.000 claims description 2
- 102100039360 Toll-like receptor 4 Human genes 0.000 claims description 2
- 102100039357 Toll-like receptor 5 Human genes 0.000 claims description 2
- 102100039387 Toll-like receptor 6 Human genes 0.000 claims description 2
- 102100039390 Toll-like receptor 7 Human genes 0.000 claims description 2
- 102100033110 Toll-like receptor 8 Human genes 0.000 claims description 2
- 102100033117 Toll-like receptor 9 Human genes 0.000 claims description 2
- 102000011408 Tripartite Motif Proteins Human genes 0.000 claims description 2
- 108010023649 Tripartite Motif Proteins Proteins 0.000 claims description 2
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 2
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims description 2
- 102100021125 Tyrosine-protein kinase ZAP-70 Human genes 0.000 claims description 2
- 239000013604 expression vector Substances 0.000 claims description 2
- 230000003834 intracellular effect Effects 0.000 claims description 2
- DAZSWUUAFHBCGE-KRWDZBQOSA-N n-[(2s)-3-methyl-1-oxo-1-pyrrolidin-1-ylbutan-2-yl]-3-phenylpropanamide Chemical compound N([C@@H](C(C)C)C(=O)N1CCCC1)C(=O)CCC1=CC=CC=C1 DAZSWUUAFHBCGE-KRWDZBQOSA-N 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 239000013603 viral vector Substances 0.000 claims description 2
- 108010087408 alpha-beta T-Cell Antigen Receptors Proteins 0.000 claims 2
- 102100026964 M1-specific T cell receptor beta chain Human genes 0.000 claims 1
- 102000006707 alpha-beta T-Cell Antigen Receptors Human genes 0.000 claims 1
- 238000000034 method Methods 0.000 description 37
- 201000011510 cancer Diseases 0.000 description 26
- 102000038030 PI3Ks Human genes 0.000 description 10
- 108091007960 PI3Ks Proteins 0.000 description 10
- 239000003112 inhibitor Substances 0.000 description 10
- 230000037361 pathway Effects 0.000 description 10
- 101001043809 Homo sapiens Interleukin-7 receptor subunit alpha Proteins 0.000 description 8
- 101001018097 Homo sapiens L-selectin Proteins 0.000 description 8
- 102100021593 Interleukin-7 receptor subunit alpha Human genes 0.000 description 8
- 102100033467 L-selectin Human genes 0.000 description 8
- 241000701022 Cytomegalovirus Species 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 4
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 description 4
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 4
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 description 4
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 230000008488 polyadenylation Effects 0.000 description 4
- 206010066476 Haematological malignancy Diseases 0.000 description 3
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 3
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 2
- 206010005003 Bladder cancer Diseases 0.000 description 2
- 241000713704 Bovine immunodeficiency virus Species 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 2
- 241000713800 Feline immunodeficiency virus Species 0.000 description 2
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 2
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 239000012828 PI3K inhibitor Substances 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
- 206010038389 Renal cancer Diseases 0.000 description 2
- 241000714474 Rous sarcoma virus Species 0.000 description 2
- 241000713311 Simian immunodeficiency virus Species 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- HGVNLRPZOWWDKD-UHFFFAOYSA-N ZSTK-474 Chemical group FC(F)C1=NC2=CC=CC=C2N1C(N=1)=NC(N2CCOCC2)=NC=1N1CCOCC1 HGVNLRPZOWWDKD-UHFFFAOYSA-N 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 208000006990 cholangiocarcinoma Diseases 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 201000004101 esophageal cancer Diseases 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 201000010982 kidney cancer Diseases 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 description 2
- 230000001124 posttranscriptional effect Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 201000005112 urinary bladder cancer Diseases 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 206010004593 Bile duct cancer Diseases 0.000 description 1
- 206010006002 Bone pain Diseases 0.000 description 1
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 1
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000713756 Caprine arthritis encephalitis virus Species 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 206010017076 Fracture Diseases 0.000 description 1
- 101000834253 Gallus gallus Actin, cytoplasmic 1 Proteins 0.000 description 1
- 102100021519 Hemoglobin subunit beta Human genes 0.000 description 1
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 1
- 108700002232 Immediate-Early Genes Proteins 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 241000283923 Marmota monax Species 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 241000713883 Myeloproliferative sarcoma virus Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102000010292 Peptide Elongation Factor 1 Human genes 0.000 description 1
- 108010077524 Peptide Elongation Factor 1 Proteins 0.000 description 1
- 102100028251 Phosphoglycerate kinase 1 Human genes 0.000 description 1
- 101710139464 Phosphoglycerate kinase 1 Proteins 0.000 description 1
- 102100037935 Polyubiquitin-C Human genes 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 108010056354 Ubiquitin C Proteins 0.000 description 1
- 208000010094 Visna Diseases 0.000 description 1
- 208000020560 abdominal swelling Diseases 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 208000026900 bile duct neoplasm Diseases 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 108010006025 bovine growth hormone Proteins 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 208000009724 equine infectious anemia Diseases 0.000 description 1
- 210000002768 hair cell Anatomy 0.000 description 1
- 102000046157 human CSF2 Human genes 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021131289A JP2021180676A (ja) | 2015-08-31 | 2021-08-11 | 抗シアリルｔｎキメラ抗原受容体 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20150122727 | 2015-08-31 | ||
| KR10-2015-0122727 | 2015-08-31 | ||
| US201662317950P | 2016-04-04 | 2016-04-04 | |
| US62/317,950 | 2016-04-04 | ||
| PCT/US2016/049493 WO2017040529A1 (en) | 2015-08-31 | 2016-08-30 | Anti-sialyl tn chimeric antigen receptors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021131289A Division JP2021180676A (ja) | 2015-08-31 | 2021-08-11 | 抗シアリルｔｎキメラ抗原受容体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018526028A JP2018526028A (ja) | 2018-09-13 |
| JP2018526028A5 true JP2018526028A5 (enExample) | 2019-10-10 |
| JP6980659B2 JP6980659B2 (ja) | 2021-12-15 |
Family
ID=58189051
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018530657A Active JP6980659B2 (ja) | 2015-08-31 | 2016-08-30 | 抗シアリルｔｎキメラ抗原受容体 |
| JP2021131289A Withdrawn JP2021180676A (ja) | 2015-08-31 | 2021-08-11 | 抗シアリルｔｎキメラ抗原受容体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021131289A Withdrawn JP2021180676A (ja) | 2015-08-31 | 2021-08-11 | 抗シアリルｔｎキメラ抗原受容体 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US11279769B2 (enExample) |
| EP (2) | EP4014996A1 (enExample) |
| JP (2) | JP6980659B2 (enExample) |
| KR (1) | KR102715016B1 (enExample) |
| CN (1) | CN108136014A (enExample) |
| AU (1) | AU2016315704B2 (enExample) |
| CA (1) | CA2996893A1 (enExample) |
| ES (1) | ES2911015T3 (enExample) |
| WO (1) | WO2017040529A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2708948T3 (es) | 2012-11-27 | 2019-04-12 | Childrens Medical Ct Corp | Elementos reguladores distales de bcl11a como dianas para la reinducción de la hemoglobina fetal |
| CN106794260B (zh) | 2014-04-25 | 2021-02-23 | 儿童医疗中心有限公司 | 治疗血红蛋白病的组合物和方法 |
| EP3763814A1 (en) | 2015-05-08 | 2021-01-13 | The Children's Medical Center Corporation | Targeting bcl11a enhancer functional regions for fetal hemoglobin reinduction |
| EP4014996A1 (en) | 2015-08-31 | 2022-06-22 | Helixmith Co., Ltd | Anti-sialyl tn chimeric antigen receptors |
| US11261441B2 (en) | 2017-03-29 | 2022-03-01 | Bluebird Bio, Inc. | Vectors and compositions for treating hemoglobinopathies |
| SG11201908844YA (en) * | 2017-03-29 | 2019-10-30 | Bluebird Bio Inc | Vectors and compositions for treating hemoglobinopathies |
| MX421249B (es) * | 2017-05-10 | 2025-02-10 | Wistar Inst | Constructos de anticuerpos de ácidos nucleicos optimizados |
| US11788087B2 (en) | 2017-05-25 | 2023-10-17 | The Children's Medical Center Corporation | BCL11A guide delivery |
| JP7414714B2 (ja) * | 2017-09-29 | 2024-01-16 | ナショナル ヘルス リサーチ インスティテューツ | 抗腫瘍および抗ウイルスｔ細胞の生存および機能性を増強する方法および組成物 |
| US20200392458A1 (en) * | 2017-11-24 | 2020-12-17 | Onk Therapeutics Limited | Modified natural killer cells and natural killer cell lines targetting tumour cells |
| PT110526B (pt) * | 2018-01-26 | 2021-02-04 | Univ Nova De Lisboa | Anticorpo, fragmento funcional ou sonda do mesmo contra antigénios tumorais |
| KR20200140799A (ko) | 2018-01-31 | 2020-12-16 | 더 위스타 인스티튜트 오브 아나토미 앤드 바이올로지 | 호흡기 세포융합 바이러스에 대하여 사용하기 위한 핵산 항체 작제물 |
| US12522811B2 (en) | 2018-05-01 | 2026-01-13 | The Children's Medical Center Corporation | Enhanced BCL11A RNP / CRISPR delivery and editing using a 3XNLS-CAS9 |
| US12350284B2 (en) | 2018-05-02 | 2025-07-08 | The Children's Medical Center Corporation | BCL11A microRNAs for treating hemoglobinopathies |
| EP3830133A1 (en) * | 2018-08-01 | 2021-06-09 | City of Hope | Tag72 targeted chimeric antigen receptor modified t cells for treatment of tag72-positive tumors |
| CN113164570B (zh) | 2018-08-08 | 2024-05-14 | 蜻蜓疗法股份有限公司 | 结合nkg2d、cd16和肿瘤相关抗原的蛋白质 |
| WO2022224242A1 (en) * | 2021-04-20 | 2022-10-27 | Ramot At Tel-Aviv University Ltd. | Humanized anti-sialyl-tn glycan antibodies and uses thereof |
| US20240216510A1 (en) * | 2021-04-20 | 2024-07-04 | Ramot At Tel-Aviv University Ltd. | Chimeric antigen receptors to sialyl-tn glycan antigen |
| MX2023013637A (es) * | 2021-05-19 | 2024-02-13 | Prec Biologics Inc | Metodos y composiciones para tratar neoplasias hematicas. |
| US20250268940A1 (en) | 2022-04-19 | 2025-08-28 | Intellia Therapeutics, Inc. | Chimeric antigen receptor compositions and uses |
| GB2619976A (en) * | 2022-06-24 | 2023-12-27 | Cellmabs S A | Humanised antibodies or functional fragments thereof against tumour antigens |
| TW202611087A (zh) * | 2024-05-14 | 2026-03-16 | 中國大陸商禮新醫藥科技（上海）有限公司 | 抗ｓｔｎ抗體及其結合物 |
| WO2026057354A1 (en) * | 2024-09-10 | 2026-03-19 | Invox Pharma Limited | Anti-sialyl-tn antigen-binding proteins |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
| US4873192A (en) | 1987-02-17 | 1989-10-10 | The United States Of America As Represented By The Department Of Health And Human Services | Process for site specific mutagenesis without phenotypic selection |
| US5858358A (en) | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
| US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5283173A (en) | 1990-01-24 | 1994-02-01 | The Research Foundation Of State University Of New York | System to detect protein-protein interactions |
| GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
| JP3540315B2 (ja) | 1991-09-23 | 2004-07-07 | メディカル リサーチ カウンシル | キメラ抗体の製造−組合せアプローチ |
| DE69334275D1 (de) | 1992-08-21 | 2009-05-20 | Univ Bruxelles | Immunoglobuline ohne Leichtkette |
| US6005079A (en) | 1992-08-21 | 1999-12-21 | Vrije Universiteit Brussels | Immunoglobulins devoid of light chains |
| WO1994025591A1 (en) | 1993-04-29 | 1994-11-10 | Unilever N.V. | PRODUCTION OF ANTIBODIES OR (FUNCTIONALIZED) FRAGMENTS THEREOF DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF $i(CAMELIDAE) |
| US7175843B2 (en) | 1994-06-03 | 2007-02-13 | Genetics Institute, Llc | Methods for selectively stimulating proliferation of T cells |
| US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
| US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| FR2777909B1 (fr) | 1998-04-24 | 2002-08-02 | Pasteur Institut | Utilisation de sequences d'adn de structure triplex pour le tranfert de sequences de nucleotides dans des cellules, vecteurs recombinants contenant ces sequences triplex |
| US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
| US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| HK1052372A1 (zh) | 2000-02-24 | 2003-09-11 | Xcyte Therapies, Inc. | 细胞的同步刺激和富集 |
| US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US6962810B2 (en) | 2000-10-31 | 2005-11-08 | University Of Notre Dame Du Lac | Methods and compositions for transposition using minimal segments of the eukaryotic transformation vector piggyBac |
| WO2002088346A2 (en) | 2001-05-01 | 2002-11-07 | National Research Council Of Canada | A system for inducible expression in eukaryotic cells |
| WO2003057171A2 (en) | 2002-01-03 | 2003-07-17 | The Trustees Of The University Of Pennsylvania | Activation and expansion of t-cells using an engineered multivalent signaling platform |
| KR100620554B1 (ko) * | 2004-06-05 | 2006-09-06 | 한국생명공학연구원 | Ｔａｇ-72에 대한 인간화 항체 |
| WO2008027384A1 (en) | 2006-08-28 | 2008-03-06 | University Of Hawaii | Methods and compositions for transposon-mediated transgenesis |
| JP2010505775A (ja) | 2006-10-04 | 2010-02-25 | クーベンハヴンス・ユニヴェルシテット | Ｍｕｃ１に対する癌特異的な免疫反応の産生及び癌特異的ｍｕｃ１抗体 |
| PH12013501201A1 (en) * | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| KR20140060541A (ko) * | 2011-09-16 | 2014-05-20 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 암을 치료하기 위한 rna 조작된 t 세포 |
| LT2884999T (lt) * | 2012-08-20 | 2021-04-12 | Fred Hutchinson Cancer Research Center | Ląstelinės imunoterapijos būdas ir kompozicijos |
| JP5372297B1 (ja) | 2012-12-20 | 2013-12-18 | 三菱電機株式会社 | 車載装置及びプログラム |
| US9108442B2 (en) | 2013-08-20 | 2015-08-18 | Ricoh Company, Ltd. | Image forming apparatus |
| EP3054974A4 (en) | 2013-10-10 | 2017-06-14 | Siamab Therapeutics, Inc. | Glycan-interacting compounds and methods of use |
| CN107074957B (zh) * | 2014-01-13 | 2021-05-07 | 希望之城公司 | 在Fc间隔物区中具有突变的嵌合抗原受体(CAR)及其使用方法 |
| EP4014996A1 (en) | 2015-08-31 | 2022-06-22 | Helixmith Co., Ltd | Anti-sialyl tn chimeric antigen receptors |
-
2016
- 2016-08-30 EP EP21217401.5A patent/EP4014996A1/en active Pending
- 2016-08-30 EP EP16842821.7A patent/EP3344295B1/en active Active
- 2016-08-30 US US15/755,819 patent/US11279769B2/en active Active
- 2016-08-30 WO PCT/US2016/049493 patent/WO2017040529A1/en not_active Ceased
- 2016-08-30 CN CN201680059597.4A patent/CN108136014A/zh active Pending
- 2016-08-30 KR KR1020187008875A patent/KR102715016B1/ko active Active
- 2016-08-30 CA CA2996893A patent/CA2996893A1/en active Pending
- 2016-08-30 AU AU2016315704A patent/AU2016315704B2/en active Active
- 2016-08-30 ES ES16842821T patent/ES2911015T3/es active Active
- 2016-08-30 JP JP2018530657A patent/JP6980659B2/ja active Active
-
2021
- 2021-08-11 JP JP2021131289A patent/JP2021180676A/ja not_active Withdrawn